Pathogen Reduction Will Not Replace Screening In Near Term – FDA’s Epstein
This article was originally published in The Gray Sheet
Executive Summary
Blood pathogen reduction technology may benefit only non-immunosuppressed patients if FDA determines that the inactivation agents pose a toxicological risk